Using MammaPrint to select patients who may not need adjuvant chemotherapy – the results of MINDACT
Mechanisms of resistance to checkpoint inhibitors in melanoma
The origins of EuropaColon
How can germline mutations distinguish risk for lethal and indolent prostate cancer?
Exciting preliminary results of M6620 combination therapy for triple negative breast cancer
Melinda L. Telli